Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-glucan + MM-10-001
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Beta-glucan + MM-10-001 is a combination therapy involving beta-glucans, which are soluble fibers derived from the cell walls of bacteria, fungi, yeasts, and some plants, and the investigational agent MM-10-001. Beta-glucans are known for their immunomodulatory properties and have been studied for their potential roles in cancer prevention and as adjuvants to chemotherapy due to their ability to stimulate immune responses. In clinical studies, oral administration of this combination has been explored in patients with locally advanced or metastatic cancers such as non-small cell lung cancer. The mechanism of action primarily involves immune system activation through modulation of innate immunity[1][2][3][6].
- Other names
- beta-glucan MM-10-001
02
Targets
CLEC7A (Dectin-1)
Beyond the preview
Go deeper on beta-glucan + MM-10-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-glucan + MM-10-001.